The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Hoitt Jason since 2019.
This trader's CIK number is 1762572.
At the time of last reporting, Hoitt Jason was the Chief Patient Officer of Stoke Therapeutics, Inc.. (stock ticker symbol STOK).
Also see all insider trading activities at Stoke Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | PRVB | 0 | $0 | 4,500 | $45,004 | 0 | $0 |
| 2020 | PRVB | 4,500 | $24,435 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | STOK | 0 | $0 | 3,712 | $120,615 | 10,000 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | DOVA | 0 | $0 | 14,741 | $240,925 | 0 | $0 |
1. Provention Bio, Inc. (PRVB)
2. Stoke Therapeutics, Inc. (STOK)
3. Dova Pharmaceuticals Inc. (DOVA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-02-10 | PRVB | Sale | 4,500 | 10.00 | 45,004 |
| 2020-03-19 | PRVB | Buy | 4,500 | 5.43 | 24,435 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-03-18 | STOK | Sale | 1,931 | 31.97 | 61,741 |
| 2026-03-17 | STOK | Sale | 1,781 | 33.06 | 58,874 |
| 2026-03-15 | STOK | Option Ex | 10,000 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-09-30 | DOVA | Sale | 2,387 | 28.00 | 66,836 |
| 2019-07-15 | DOVA | Sale | 7,580 | 15.77 | 119,536 |
| 2019-06-28 | DOVA | Sale | 2,387 | 14.09 | 33,620 |
| 2019-04-08 | DOVA | Sale | 2,387 | 8.77 | 20,933 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hoitt Jason (Chief Patient Officer of Stoke Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.